核糖体失活蛋白:寻找生物功能的酶

Q Pharmacology, Toxicology and Pharmaceutics Anales De La Real Academia Nacional De Farmacia Pub Date : 2022-12-31 DOI:10.53519/analesranf.2022.88.05.15
Tomás Girbés Juan, D. Cordoba Díaz
{"title":"核糖体失活蛋白:寻找生物功能的酶","authors":"Tomás Girbés Juan, D. Cordoba Díaz","doi":"10.53519/analesranf.2022.88.05.15","DOIUrl":null,"url":null,"abstract":"Ribosome-inactivating proteins (RIPs) are enzymes (N-glycosidases classified as rRNA N-glycohydrolases, EC 3.2.2.22), mostly of plant origin, but also of bacterial, fungal and algal origin, which cause irreversible inhibition of protein biosynthesis carried out by ribosomes of superior organisms and some bacteria. The enzymatic activity consists of specific depurination of ribosomes that renders them unable to interact with elongation factor 2 in eukaryotes and elongation factor G in prokaryotes. The best-known RIPs, ricin and abrin, consisting of two polypeptide chains (type 2), an enzymatic chain and a lectin chain specific for D-galactose and galactosides, are extremely toxic because they can be internalised in cells by binding to plasma membrane receptors, entering the cytoplasm, reaching the Golgi apparatus, and then reaching the rough endoplasmic reticulum, where they are transferred to the cytosol and there inactivate ribosomes. The most abundant RIPs possess only one enzymatic chain (type 1) and do not possess the toxicity of ricin and abrin. Their biological function in plants is currently unknown, although different hypotheses have been proposed for their mediation in plant stress response and against pathogens. RIPs have found an interesting application in the construction of immunotoxins and conjugates in experimental cancer therapy. The formulation of RIPs into nanoparticles, has been used to optimize their biopharmaceutical and pharmacokinetic properties and for diagnostic purposes.\n\nKeywords: RIP; enzyme; function; inmunotoxin; drug targeting","PeriodicalId":50795,"journal":{"name":"Anales De La Real Academia Nacional De Farmacia","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ribosome inactivating proteins: Enzymes in search of biological function\",\"authors\":\"Tomás Girbés Juan, D. Cordoba Díaz\",\"doi\":\"10.53519/analesranf.2022.88.05.15\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Ribosome-inactivating proteins (RIPs) are enzymes (N-glycosidases classified as rRNA N-glycohydrolases, EC 3.2.2.22), mostly of plant origin, but also of bacterial, fungal and algal origin, which cause irreversible inhibition of protein biosynthesis carried out by ribosomes of superior organisms and some bacteria. The enzymatic activity consists of specific depurination of ribosomes that renders them unable to interact with elongation factor 2 in eukaryotes and elongation factor G in prokaryotes. The best-known RIPs, ricin and abrin, consisting of two polypeptide chains (type 2), an enzymatic chain and a lectin chain specific for D-galactose and galactosides, are extremely toxic because they can be internalised in cells by binding to plasma membrane receptors, entering the cytoplasm, reaching the Golgi apparatus, and then reaching the rough endoplasmic reticulum, where they are transferred to the cytosol and there inactivate ribosomes. The most abundant RIPs possess only one enzymatic chain (type 1) and do not possess the toxicity of ricin and abrin. Their biological function in plants is currently unknown, although different hypotheses have been proposed for their mediation in plant stress response and against pathogens. RIPs have found an interesting application in the construction of immunotoxins and conjugates in experimental cancer therapy. The formulation of RIPs into nanoparticles, has been used to optimize their biopharmaceutical and pharmacokinetic properties and for diagnostic purposes.\\n\\nKeywords: RIP; enzyme; function; inmunotoxin; drug targeting\",\"PeriodicalId\":50795,\"journal\":{\"name\":\"Anales De La Real Academia Nacional De Farmacia\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anales De La Real Academia Nacional De Farmacia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.53519/analesranf.2022.88.05.15\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anales De La Real Academia Nacional De Farmacia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53519/analesranf.2022.88.05.15","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

摘要

核糖体失活蛋白(RIPs)是一种酶(n -糖苷酶分类为rRNA n -糖水解酶,EC 3.2.2.22),主要来源于植物,也有细菌、真菌和藻类,它对优势生物和某些细菌的核糖体进行蛋白质生物合成产生不可逆的抑制作用。酶活性包括核糖体的特异性去嘌呤化,使它们不能与真核生物中的延伸因子2和原核生物中的延伸因子G相互作用。最著名的rip,蓖麻毒素和蓖麻毒素,由两条多肽链(2型),一条酶链和一条d -半乳糖和半乳糖苷特有的凝集素链组成,具有极大的毒性,因为它们可以通过与质膜受体结合在细胞内,进入细胞质,到达高尔基体,然后到达粗内质网,在那里它们被转移到细胞质并在那里使核糖体失活。最丰富的rip只有一个酶链(1型),不具有蓖麻毒素和蓖麻毒素的毒性。它们在植物中的生物学功能目前尚不清楚,尽管人们提出了不同的假设,认为它们在植物应激反应和抗病原体中的介导作用。rip在构建免疫毒素和结合物的实验癌症治疗中发现了一个有趣的应用。rip纳米颗粒的配方已被用于优化其生物制药和药代动力学特性,并用于诊断目的。关键词:裂缝;酶;函数;inmunotoxin;药物的靶向
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Ribosome inactivating proteins: Enzymes in search of biological function
Ribosome-inactivating proteins (RIPs) are enzymes (N-glycosidases classified as rRNA N-glycohydrolases, EC 3.2.2.22), mostly of plant origin, but also of bacterial, fungal and algal origin, which cause irreversible inhibition of protein biosynthesis carried out by ribosomes of superior organisms and some bacteria. The enzymatic activity consists of specific depurination of ribosomes that renders them unable to interact with elongation factor 2 in eukaryotes and elongation factor G in prokaryotes. The best-known RIPs, ricin and abrin, consisting of two polypeptide chains (type 2), an enzymatic chain and a lectin chain specific for D-galactose and galactosides, are extremely toxic because they can be internalised in cells by binding to plasma membrane receptors, entering the cytoplasm, reaching the Golgi apparatus, and then reaching the rough endoplasmic reticulum, where they are transferred to the cytosol and there inactivate ribosomes. The most abundant RIPs possess only one enzymatic chain (type 1) and do not possess the toxicity of ricin and abrin. Their biological function in plants is currently unknown, although different hypotheses have been proposed for their mediation in plant stress response and against pathogens. RIPs have found an interesting application in the construction of immunotoxins and conjugates in experimental cancer therapy. The formulation of RIPs into nanoparticles, has been used to optimize their biopharmaceutical and pharmacokinetic properties and for diagnostic purposes. Keywords: RIP; enzyme; function; inmunotoxin; drug targeting
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.13
自引率
0.00%
发文量
7
期刊介绍: The Anales de la Real Academia Nacional de Farmacia� embraces all aspects of pharmaceutical sciences and is a quarterly journal that publishes basic and applied research on pharmaceutical sciences and related areas. It is a medium for reporting selected original and significant contributions to new pharmaceutical knowledge.
期刊最新文献
Therapeutic repositioning: importance of new therapeutic indications approved for old medicines The mRNA COVID 19 vaccine: More than a drug? Detection and management of a case of drug-resistant hypertension Galenic development of a capsule containing rosuvastatin, repaglinide, and olmesartan mini-tablets for the treatment of metabolic syndrome Novel drugs recently authorized by ema and fda (Q2, 2024)
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1